A Phase I / II Clinical Study Of Enadenotucirev Administered Intraperitoneally: Dose Finding and Proof of Concept in Platinum-Resistant Epithelial Ovarian Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 21 Feb 2017
At a glance
- Drugs Enadenotucirev (Primary) ; Paclitaxel
- Indications Ovarian cancer
- Focus Adverse reactions; Proof of concept
- Acronyms OCTAVE
- Sponsors PsiOxus Therapeutics
- 08 Sep 2016 Planned End Date changed from 1 Mar 2017 to 1 Jan 2018.
- 08 Sep 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Nov 2017.
- 07 Jun 2016 Interim results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology